A Novel Broad-Host-Range Phage for Treatment of Mouse Model of Escherichia coli Urinary Tract Infection doi.org/10.26538/tjnpr/v6i4.6
Main Article Content
Abstract
The increasing emergence of drug resistance in pathogens of urinary tract infections (UTIs) has resulted in a pressing need to develop new approaches to control this infection. This study is aimed at isolating broad-host-range phage active against isolates of uropathogenic Escherichia coli and other bacterial pathogens causing UTIs and to study its therapeutic potential on mouse model of chronic UTIs. The broad-host-phage was isolated through enrichment of E. coli isolates with sewage water and detected by spot lysis method, growth inhibition assay and top plaque assay. A novel broad-host-range phage, PEC34, was isolated and showed a 100% lytic activity towards UPEC, whereas other isolated phages showed a 12-30% lytic activity. The phage PEC34 showed lytic activity against Gram-negative pathogens of UTI like Proteus mirabilis, Citrobacter freundii, Klebsiella oxytoca and Enterobacter cloacae, but showed no lytic activity against Pseudomonas aeruginosa nor Staphylococcus aureus. The phage therapy of mouse model of chronic UTI by the broad-host -range phage PEC34 through tran surethral and intraperitoneal injection of 100 µL (1011 plaque forming units (PFU) of phage preparation on day 10 after the establishment of the infection resulted in clearance of pathogenic bacteria from the urine of mice and homogenates of bladders and kidneys of sacrificed mice after only 24 h, whereas therapy by a narrow host-range phage PEC80 showed no such effects. The phage P34 could be a strong candidate for treatment of UTIs and other infections caused by bacteria sensitive to lytic action of the phage.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004; 2:132-140.
Ballesteros-Monrreal, MG, Arenas-Hernández MMP, Enciso-Martínez Y, Martínez-de la Peña CF, Rocha-Gracia RC, Lozano-Zaraín P, Navarro-Ocaña A, Martínez-Laguna Y, de la Rosa-López R. Virulence and Resistance Determinants of Uropathogenic Escherichia coli Strains Isolated from Pregnant and Non-Pregnant Women from Two States in Mexico. Infect Drug Resist. 2020; 13:295-310.
Mahony M, McMullan B, Brown J, Kennedy SE. Multidrug-resistant organisms in urinary tract infections in children. Pediatr Nephrol. 2020; 35:1563-1573.
Qadir MI. Phage therapy: A modern tool to control bacterial infections. Pak J Pharm Sci. 2015; 28:265-270.
Mohsen S, Dickinson JA, Somayaji R. Update on the adverse effects of antimicrobial therapies in community practice. Canadian family physician Medecin de famille canadien, Canadian family physician Medecin de famille canadien 2020; 66:651-659.
Sybesma W, Zbinden R, Chanishvili N, Kutateladze M, Chkhotua A, Ujmajuridze A, Mehnert U, Kessler T. M. Bacteriophages as Potential Treatment for Urinary Tract Infections. Front Microbiol. 2016; 7:Article No. 465.
Jensen EC, Schrader HS, Rieland B, Thompson TL, Lee KW, Nickerson KW, Kokjohn TA. Prevalence of broadhost-range lytic bacteriophages of Sphaerotilus natans, Escherichia coli, and Pseudomonas aeruginosa. Appl Environ Microbiol. 1998; 64:575-580.
Xu Y, Peng DR, Xiong HY, Zhang XN, Su MQ, Sun YQ, Hao XK. Study on the nucleic acid of E. coli bacteriophage with broad host range and its sterilization effect to sewage samples from the environment. Zhonghua Liu Xing Bing Xue Za Zhi. 2005; 26:356-360.
Namura M, Hijikata T, Miyanaga K, Tanji Y. Detection of Escherichia coli with fluorescent labeled phages that have a broad host range to E. coli in sewage water. Biotechnol Prog. 2008; 24:481-486.
Ghasemian A, Bavand M, Moradpour Z. A broad-host range coliphage against a clinically isolated E. coli O157: isolation and characterization. J AppL Pharm Sci. 2017; 7:123-128.
Kumari S, Harjai K, Chhibber S. Isolation and characterization of Klebsiella pneumoniae specific
bacteriophages from sewage samples. Folia Microbiol. 2010; 55:221-227.
Tan GH, Nordin M, Napsiah AB. Isolation and characterization of lytic bacteriophages from sewage water (Pengasingan dan pencirian bakteriofaj daripada air kumbahan). J Trop Agric Food Sci. 2008; 36:1-5.
Jassim SA, Abdulamir AS, Abu Bakar F. Novel phagebased bio-processing of pathogenic scherichia coli and its biofilms. World J Microbiol Biotechnol. 2012; 28:47-60.
Knezevic P and Petrovic O. A colorimetric microtiter plate method for assessment of phage effect on Pseudomonas aeruginosa biofilm. J Microbiol Meth. 2008; 74:114-118.
Sharma S, Harjai K, Mittal R. Enhanced siderophore production and mouse kidney pathogenicity in Escherichia coli growth in urine. J Med Microbiol. 1991; 35:325-329.
Chin JL, Kadhim SA, Batislam E, Karlik SJ, Garcia BM, Nickel JC, Morales A. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol. 1996; 156:1189-1193.
Asahara T, Nomoto K, Watanuki M, Yokokura T. Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother. 2001; 45:1751-1760.
Tóthová L, Celec P, Bábíčková J, Gajdošová J, Al-Alami H, Kamodyova N, Drahovská H, Liptáková A, Turňa J, Hodosy J. Phage therapy of Cronobacter-induced urinary tract infection in mice. Med Sci Monit. 2011; 17(7):BR173-BR178.
Ørskov F and Ørskov I. Serotyping of Escherichia coli. Methods Microbiol. 1984; 14:43-112.
Hopkins WJ, Gendron-Fitzpatrick A, Balish E, Uehling D. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect Immunol. 1998; 66:2798-2802.
Letkiewicz S, Międzybrodzki R, Kłak M, Jończyk E, Weber-Dąbrowska B, Górski A. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol Med Microbiol. 2010; 60:99-112.
Tóthová L, Celec P, Bábíčková J, Gajdošová J, Al-Alami H, Kamodyova N, Drahovská H, Liptáková A, Turňa J, Hodosy J. Phage therapy of Cronobacter-induced urinary tract infection in mice. Med Sci Monit. 2011; 17:173-178.
Bolocan AS, Callanan J, Forde A, Ross P, Hill C. Phage therapy targeting Escherichia coli-a story with no end?. FEMS Microbiol Lett. 2016; 363:1-5.
Arenas-Hernández MMP, Martínez-Laguna Y, Torres AG. Clinical Implications of Enteroadherent Escherichia coli. Curr Gastroenterol Rep. 2012; 14:386-394.
Karam MR, Habibi M, Bouzari S. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli. Mol Immunol. 2019; 108:56-67.
Kelly D, McAuliffe O, Ross RP, O'Mahony J, Coffey A. Development of a broad-host-range phage cocktail for biocontrol. Bioeng Bugs. 2011; 2:31-37.
Nasr-Eldin MA, Abo EL-Maaty SA, EL-Dougdoug KA, Hazaa MM., Abdel-mageed AH. Characterization and development of a phage cocktail for Escherichia coli causing gastrointestinal
diseases. J Bas ic Environ Sci. 2011; 5:115-122.
Furfaro LL, Chang BJ, Payne M. Applications for Bacteriophage Therapy during Pregnancy and the Perinatal Period. Front Microbiol. 2018; 8:2660.
Cafora M, Deflorian G, Forti F, Ferrari L, Binelli G, Briani F, Ghisotti D, Pistocchi A. Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model. Sci Rep. 2019; 9:1527.
Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R. Therapeutic Characterization and Efficacy of Bacteriophage Cocktails Infecting Escherichia coli, Klebsiella pneumoniae, and Enterobacter Species. Front Microbiol. 2019; 10:574.